Lumos Diagnostics (ASX:LDX), a developer of rapid point-of-care diagnostic technologies, has entered into a new distribution agreement with the Interlux Group to commercialise its FebriDx test across the Baltic region, including Lithuania, Estonia and Latvia.
Interlux, a medical distributor established in 1994 with more than 100 sales specialists serving over 1,000 customers, will manage sales, distribution and inventory for the product and has placed an initial stocking order to support immediate market availability.
The agreement enables FebriDx to be supplied into primary care, urgent care and outpatient settings, leveraging Interlux's established logistics network and customer base.
Lumos said the partnership strengthens its growing European distribution footprint, complementing existing agreements with Henry Schein in markets such as the UK, Spain, Portugal and the Netherlands, as the company continues to expand access to FebriDx through experienced regional partners.
At the time of reporting, Lumos Diagnostics' share price was $0.26.